Strategy

trg-entree-estTransgene operates under a business model based around its expertise and fully integrated capabilities for the discovery and development of novel viral vector-based targeted immunotherapeutics.

Therapeutic partnering strategy: out-licensing to major pharmaceutical partners

Transgene uses its in-house discovery and development resources to discover, evaluate pre-clinically, and then test in human clinical studies a wide range of novel immunotherapeutics. The company focuses on two therapeutic areas – oncology and infectious diseases.

Transgene may seek to partner these programs with leading pharmaceutical partners in the relevant disease areas as they reach key pre-clinical or clinical development milestones.

R&D collaborations and Open Innovation strategy with major pharmaceutical partners and/or specialized biotechs22395305_blog

Transgene has unique expertise in developing targeted immunotherapeutics utilizing a wide range of viral vectors. This expertise, combined with a comprehensive infrastructure for drug discovery, development, and manufacturing, including formulation and process development, makes a powerful drug creation platform.

Transgene is therefore ideally placed to become the immunotherapeutic partner of choice for pharmaceutical companies looking to enter the field of viral vector-based immunotherapeutics or to bolster their internal efforts in this area.

Transgene’s model for R&D collaborations is extremely flexible to meet its partners’ needs, including:

– Utilization of a variety of viral vector platforms, including MVA, oncolytic vaccinia and adenovirus platforms.

– R&D in the areas of infectious disease and oncology.

– Collaborations based on different R&D concepts.

These range from de novo therapeutic discovery and development of immunotherapeutics for use as a standalone therapy or in combination with other treatments, to vectorization of a partner’s therapeutic molecule within a single virus-based therapeutic to provide a) more effective targeting, b) production of the partner’s therapeutic “in-situ” and c) potent “single administration” polyvalent therapies.

– Ability to take programs to different stages of development

Transgene’s capabilities run from discovery through clinical proof-of-concept, including manufacturing.

Meetings

The International Liver Congress™
European Association for the Study of the Liver (EASL)
Barcelona, Spain
April 13-17, 2016

American Association for Cancer Research (AACR) Annual Meeting
New Orleans, LA USA
April 16-20, 2016

BioEquity Europe
Copenhagen, Denmark
May 10-11, 2016

American Society of Clinical Oncology (ASCO) Annual Meeting
Chicago, IL USA
June 3-7, 2016

BIO International Convention
San Francisco, CA USA
June 6-9, 2016

Immuno-oncology Summit
Boston, MA États-Unis
Auguts 29-30, 2016

European Society for Medical Oncology (ESMO) Congress
Copenhagen, Denmark
October 7-11, 2016

BIO-Europe
Cologne, Germany
November 7-9, 2016

The Liver Meeting®
of the American Association for the Study of Liver Diseases (AASLD)
Boston, MA USA
November 11-15, 2016